144 related articles for article (PubMed ID: 38453011)
1. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis.
Ji J; Zhang Z; Hou Z; Qiu G; Mi S; Jin Z; Huang J
Clin Res Hepatol Gastroenterol; 2024 Apr; 48(4):102313. PubMed ID: 38453011
[TBL] [Abstract][Full Text] [Related]
2. Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
Duan R; Gong F; Wang Y; Huang C; Wu J; Hu L; Liu M; Qiu S; Lu L; Lin Y
World J Surg Oncol; 2023 Mar; 21(1):120. PubMed ID: 37004052
[TBL] [Abstract][Full Text] [Related]
3. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
Front Immunol; 2022; 13():913464. PubMed ID: 35677059
[TBL] [Abstract][Full Text] [Related]
4. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
Liu JN; Li JJ; Yan S; Zhang GN; Yi PS
Front Oncol; 2023; 13():1074793. PubMed ID: 36910612
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients.
Li N; Chen J
Ir J Med Sci; 2022 Dec; 191(6):2611-2617. PubMed ID: 35083645
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of raltitrexed-eluting CalliSpheres
Sun Z; Jiao D; Fang Y; Liu Y; Xu K; Zhang C; Huang Y; Han X
Ther Adv Med Oncol; 2024; 16():17588359241229661. PubMed ID: 38362379
[TBL] [Abstract][Full Text] [Related]
7. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Kong SY; Song JJ; Jin YQ; Deng MJ; Yan JX
Acta Clin Belg; 2023 Apr; 78(2):171-179. PubMed ID: 35587164
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of transarterial chemoembolization combined with targeted therapy and immunotherapy versus with targeted monotherapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
Feng J; Zhao Y; Zhai L; Zhou J
Medicine (Baltimore); 2024 May; 103(18):e38037. PubMed ID: 38701263
[TBL] [Abstract][Full Text] [Related]
9. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
Wang M; Sun L; Han X; Ren J; Li H; Wang W; Xu W; Liang C; Duan X
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102060. PubMed ID: 36473631
[TBL] [Abstract][Full Text] [Related]
10. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
[TBL] [Abstract][Full Text] [Related]
11. TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial sequential analysis.
Liu J; Wang P; Shang L; Zhang Z; Tian Y; Chen X; Ma Y; Shao H
Hepatol Int; 2024 Apr; 18(2):595-609. PubMed ID: 37843788
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of camrelizumab combined with TACE for hepatocellular carcinoma: a systematic review and meta-analysis.
Xian F; Song XW; Bie J; Zhao CX; Zhang GJ; Xu GH
Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):687-701. PubMed ID: 38305611
[TBL] [Abstract][Full Text] [Related]
13. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
[TBL] [Abstract][Full Text] [Related]
14. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
Tang J; Huang Z; Xu J; Lv Q; Wang P
Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Huang K; Zhou Q; Wang R; Cheng D; Ma Y
J Gastroenterol Hepatol; 2014 May; 29(5):920-5. PubMed ID: 24224722
[TBL] [Abstract][Full Text] [Related]
16. Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads.
Bi Y; Shi X; Ren J; Yi M; Han X
Sci Rep; 2022 May; 12(1):8136. PubMed ID: 35581365
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of transarterial chemoembolization with drug-eluting beads combined with systemic chemotherapy and targeted therapy in colorectal cancer liver metastasis.
Chen YC; Huang CW; Li CC; Chang TK; Su WC; Chen PJ; Yeh YS; Chang YT; Tsai HL; Shih MP; Wang JY
World J Surg Oncol; 2023 Dec; 21(1):378. PubMed ID: 38041083
[TBL] [Abstract][Full Text] [Related]
18. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
[No Abstract] [Full Text] [Related]
19. Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review.
Yang B; Liang J; Qu Z; Yang F; Liao Z; Gou H
PLoS One; 2020; 15(2):e0227475. PubMed ID: 32074102
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.
Wu SJ; Ruan DD; Wu QY; Tang Y; Zhang JH; Cai SL; Zhou YF; Luo JW; Fang ZT
J Hepatocell Carcinoma; 2023; 10():807-820. PubMed ID: 37292114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
